Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Leases (2022 - 2024)

BioXcel Therapeutics has reported Operating Leases over the past 3 years, most recently at $65000.0 for Q4 2024.

  • Quarterly results put Operating Leases at $65000.0 for Q4 2024, down 85.23% from a year ago — trailing twelve months through Dec 2024 was $65000.0 (down 85.23% YoY), and the annual figure for FY2024 was $65000.0, down 85.23%.
  • Operating Leases for Q4 2024 was $65000.0 at BioXcel Therapeutics, down from $161000.0 in the prior quarter.
  • Over the last five years, Operating Leases for BTAI hit a ceiling of $1.0 million in Q1 2022 and a floor of $65000.0 in Q4 2024.
  • Median Operating Leases over the past 3 years was $573000.0 (2023), compared with a mean of $562666.7.
  • Biggest five-year swings in Operating Leases: plummeted 31.61% in 2023 and later crashed 85.23% in 2024.
  • BioXcel Therapeutics' Operating Leases stood at $786000.0 in 2022, then crashed by 44.02% to $440000.0 in 2023, then crashed by 85.23% to $65000.0 in 2024.
  • The last three reported values for Operating Leases were $65000.0 (Q4 2024), $161000.0 (Q3 2024), and $256000.0 (Q2 2024) per Business Quant data.